Julia Ziegengeist, PharmD, BCOP

Pharmacists manage QTc monitoring with ribociclib, confirm QTcF, assess interactions, hold and dose-reduce therapy, and guide CDK4/6 switches for toxicity or cost.

Learn how pharmacists spot and manage ribociclib QTc prolongation, handle drug interactions, and switch CDK4/6 inhibitors for safety and cost.

Multidisciplinary breast cancer care boosts CDK4/6 adherence with nurse and pharmacy check-ins, targeted toxicity scripts, and early intervention to prevent drop-offs.

How multidisciplinary breast cancer teams use nurses and specialty pharmacists to catch CDK4/6 inhibitor toxicities early and keep patients on therapy.

Learn how CDK4/6 inhibitor schedules vary and how pharmacists boost adherence, manage nausea, labs, QTc, and drug interactions.

How CDK4/6 inhibitors stack up in metastatic HR+ breast cancer, with trial survival data, real‑world tolerability, and visceral crisis caveats.

Learn how teams flag adjuvant CDK4/6 candidates at diagnosis, avoid patients slipping through cracks, and improve real-world use.

Five-year NATALEE updates show ribociclib boosts invasive disease-free survival in broader early breast cancer risk groups, guiding therapy choice.

The panelists examined the 5-year follow-up data from the NATALEE trial, which evaluated the addition of ribociclib to a nonsteroidal aromatase inhibitor in patients with early breast cancer. Faculty examined how the patient population, study design, and clinical endpoints in this trial differed from those used in the monarchE trial. The discussion highlighted important distinctions in eligibility criteria and outcome measures that may influence interpretation of results. Experts reviewed the key efficacy findings from the 5-year analysis and discuss the safety profile observed with ribociclib in the adjuvant setting. Particular attention was given to how these outcomes inform the role of CDK4/6 inhibition in early-stage disease. Faculty shared their perspectives on the most meaningful clinical takeaways from the updated data. Finally, the panel compared the findings from NATALEE with the long-term results from monarchE and discuss how these studies together may shape treatment strategies and decision-making in clinical practice.

Throughout the conversation, the experts provide a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

Pharmacists guide HR+ breast cancer CDK4/6 therapy, tackling interactions, costs, and toxicity monitoring, and applying new clinical trial insights.

CDK4/6 inhibitor therapies must by tailored by comorbidities, interactions, cost, and coordinated labs with pharmacist expertise to support high-risk patients.

Julia Ziegengeist, PharmD, BCOP offers insights for pharmacists navigating adjuvant and neoadjuvant treatment of breast cancer.